Replies to post #240224 on Bioelectronics Corp (BIEL)

[srinsocal]

Who was leading BIEL when it....

* Signed 3 US OTC OEM Deals? One we have confirmed as being DJO Global

* Signed a US Marketing Agreement for RecoveryRx? 250 Trained Sales Reps in the field, several Hospital Systems already signed up for RecoveryRx

* Signed an International Licensing Deal for ActiPatch?

* Signed a RecoveryRx Distribution Deal for Europe?

* Signed a RecoveryRx Distribution Deal for Asia?

* Signed a RecoveryRx Distribution Deal for Latin America?

* Signed a RecoveryRx Distribution Deal for Middle East/North Africa


All accomplished in one year, most of that time under the cloud of a global pandemic that has infected 52 million and killed 1.28 million.


I prefer to focus on the tremendous successes of 2020 rather than what happened years ago.

BIEL is now a viable company or DJO would not be selling Products embossed with, "Powered by ActiPatch".

[Simpsonly]

Hmmm, 20 reasons for something, all from the past, without much looking at where things are today and where they may go, looking forward! I try to limit SWOT Analysis points to three or less per category.

S
- BIEL owns ActiPatch, an amazing, patented, FDA cleared, drug-free, side-effect free pain medical device that reduces pain and edema substantially and stimulates healing at the cellular level.
- Substantial OEM global players recognize potential markets of 2 billion plus users
- Numerous management changes and positive turnaround performance last 4Q

W
- Share price sub-penny for years due to lack of management skillset in the pharma/pain sector and predictable results
- Share structure remains heavily conflicted/biased as a result of previous management self-dealing. No longer with company, requires resolution

O
- OEM deals are real and progressing every day
- Current management is firing on all cylinders and there is a real opportunity that naysayers will continue to have diminishing effects on investor attitude
- Continuing low share price makes BIEL a Pink Sheet sleeper, providing management addresses the Whelan family shares structure issue

T
- Share structure inappropriately favors heirs of previous CEO
- Disgruntled stockholders

Every day is a day of great opportunity for BIEL! ActiPatch and RecoveryRx were never the issue blocking success. Current management is quickly reversing BIEL's past poor performance.